Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 30 citing articles:

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona Yaeger, Jared Weiss, Meredith Pelster, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 44-54
Open Access | Times Cited: 288
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 265-270
Open Access | Times Cited: 34
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 982-993
Open Access | Times Cited: 28
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Patrick W. Underwood, Samantha M. Ruff, Timothy M. Pawlik
Cells (2024) Vol. 13, Iss. 3, pp. 245-245
Open Access | Times Cited: 24
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
Julien Taı̈eb, Frank A. Sinicrope, Levi D. Pederson, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 1025-1034
Open Access | Times Cited: 27
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
John H. Strickler, Takayuki Yoshino, Kendall Stevinson, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. e981-e994
Open Access | Times Cited: 19
Targeting KRASG12C in colorectal cancer: the beginning of a new era
Davide Ciardiello, Brigida Anna Maiorano, Erika Martinelli
ESMO Open (2022) Vol. 8, Iss. 1, pp. 100745-100745
Open Access | Times Cited: 24
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Lindor Qunaj, Michael May, Alfred I. Neugut, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications
Hasan Çağrı Yıldırım, Damla Günenç, Elvina Almuradova, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 408-408
Open Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Emmanuel Kokori, Gbolahan Olatunji, Ikponmwosa Jude Ogieuhi, et al.
International Journal of Clinical Oncology (2025)
Closed Access
KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
Alessandro Ottaiano, Francesco Sabbatino, Francesco Perri, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3579-3579
Open Access | Times Cited: 12
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Bernhard Doleschal, Andreas Petzer, Holger Rumpold
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 17
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer
Cosimo Rasola, Pierre Laurent–Puig, Thierry André, et al.
European Journal of Cancer (2023) Vol. 194, pp. 113321-113321
Open Access | Times Cited: 9
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
Débora Contreras Toledo, Paula Jiménez‐Fonseca, Carlos López, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 5, pp. 777-787
Closed Access | Times Cited: 3
Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer
Gözde Kavgacı, Ömer Dızdar, Şuayib Yalçın
Anti-Cancer Drugs (2024)
Closed Access | Times Cited: 3
KRAS: Druggable at Last
Benjamin Herzberg, Gulam A. Manji
The Oncologist (2023) Vol. 28, Iss. 4, pp. 283-286
Open Access | Times Cited: 7
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Paolo Ciracì, Vittorio Studiale, Ada Taravella, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
Davide Ciardiello, Cinzia Chiarazzo, Vincenzo Famiglietti, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100567-100567
Open Access | Times Cited: 10
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Annie Xiao, Marwan Fakih
Clinical Colorectal Cancer (2024) Vol. 23, Iss. 3, pp. 199-206
Closed Access | Times Cited: 1
Precision oncology for KRASG12C-mutant colorectal cancer
Federica Di Nicolantonio, Alberto Bardelli
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 355-356
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top